Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Malar J ; 20(1): 341, 2021 Aug 14.
Article in English | MEDLINE | ID: mdl-34391426

ABSTRACT

BACKGROUND: The relapsing nature of Plasmodium vivax infection is a major barrier to its control and elimination. Factors such as adequate dosing, adherence, drug quality, and pharmacogenetics can impact the effectiveness of radical cure of P. vivax and need to be adequately evaluated. CYP2D6 pathway mediates the activation of primaquine (primaquine) into an active metabolite(s) in hepatocytes, and impaired activity has been linked to a higher risk of relapse. CASES PRESENTATION: Three patients diagnosed with P. vivax malaria presented repeated relapses after being initially treated with chloroquine (25 mg/kg) and primaquine (3.5 mg/kg in 14 days) at a non-endemic travel clinic. Recurring episodes were subsequently treated with a higher dose of primaquine (7 mg/kg in 14 days), which prevented further relapses in two patients. However, one patient still presented two episodes after a higher primaquine dose and was prescribed 300 mg of chloroquine weekly to prevent further episodes. Impaired CYP2D6 function was observed in all of them. CONCLUSION: Lack of response to primaquine was associated with impaired CYP2D6 activity in three patients presenting multiple relapses followed in a non-endemic setting. Higher primaquine dosage was safe and effectively prevented relapses in two patients and should be further investigated as an option in Latin America. It is crucial to investigate the factors associated with unsuccessful radical cures and alternative therapeutic options.


Subject(s)
Cytochrome P-450 CYP2D6/deficiency , Malaria, Vivax/prevention & control , Plasmodium vivax/drug effects , Primaquine/therapeutic use , Secondary Prevention , Adult , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged
3.
J Neurol Sci ; 325(1-2): 174-5, 2013 Feb 15.
Article in English | MEDLINE | ID: mdl-23294497

ABSTRACT

Many HIV infected patients are at risk for HTLV-I co-infection worldwide. These patients exhibit abnormally high CD4+ T lymphocyte counts that are not a reliable parameter of the immune status. We report a HIV/HTLV co-infected patient who developed progressive multifocal leukoencephalopathy despite of a high CD4+ T lymphocyte count emphasizing that this situation can be observed in regions around the world where HTLV-I infection is prevalent.


Subject(s)
Coinfection/diagnosis , HIV Infections/diagnosis , HTLV-I Infections/diagnosis , Leukoencephalopathy, Progressive Multifocal/diagnosis , Adult , Coinfection/complications , HIV Infections/complications , HTLV-I Infections/complications , Humans , Leukoencephalopathy, Progressive Multifocal/complications , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...